Antithrombotic outcome trials in acute coronary syndromes: Seeking the optimal balance between safety and efficacy

Additional Metadata
Keywords	acute coronary syndrome, anticoagulant therapy, article, bleeding, coronary artery bypass graft, drug efficacy, drug safety, human, phase 2 clinical trial (topic), phase 3 clinical trial (topic), priority journal, risk benefit analysis
Persistent URL	doi.org/10.1093/eurheartj/eht013, hdl.handle.net/1765/40991
Journal	European Heart Journal
Organisation	Erasmus MC: University Medical Center Rotterdam
Citation APA APA Style APA-ALL Style AAA Style Cell Style Chicago Style Harvard Style IEEE Style MLA Style Nature Style Vancouver Style American-Institute-of-Physics Style Council-of-Science-Editors Style BibTex Format Endnote Format RIS Format CSL Format DOIs only Format	Verheugt, F., Clemmensen, P. M., Mehran, R., Agewall, S., Pocock, S. J., Goldstein, S., Torp-Pedersen, C. T., Simoons, M., Borer, J., Khder, Y., Burton, J. P., Deliargyris, E., McMurray, J., Berkowitz, S., Stough, W. G.& Zannad, F. (2013). Antithrombotic outcome trials in acute coronary syndromes: Seeking the optimal balance between safety and efficacy. European Heart Journal, 34(22), 1621–1629.https://doi.org/10.1093/eurheartj/eht013

Publication